Search Within

Tiffany A Traina

Formats
  1. Meeting Abstract (140)
  2. Journal Article (95)
  3. Book Section (8)
  4. Review (6)
  5. Book Whole (2)
  6. Guidelines (1)
  7. Miscellaneous (1)
Groups
  1. Breast Medicine Service (253)
  2. Department of Medicine (253)
  3. Solid Tumor Oncology Division (253)
  4. Survivorship Research (253)
  5. Epidemiology and Biostatistics (101)
  6. Biostatistics Service (87)

More Groups

People
  1. Clifford Hudis (95)
  2. Sujata Patil (62)
  3. Ayca Gucalp (59)
  4. Larry Norton (56)
  5. Maura Dickler (34)
  6. Diana Lake (33)

More People

Years
  1. 2025 (6)
  2. 2024 (16)
  3. 2023 (8)
  4. 2022 (13)
  5. 2021 (17)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (79)
  2. Cancer Research (44)
  3. Breast Cancer Research and Treatment (16)
  4. Annals of Oncology (14)
  5. Clinical Cancer Research (11)
  6. Clinical Breast Cancer (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (80)
  2. American Association for Cancer Research (55)
  3. Springer (33)
  4. Elsevier Inc. (23)
  5. Oxford University Press (16)
  6. Future Medicine (5)

More Publishers

Results (253)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment patterns for metastatic hormone receptor-positive breast cancer: Comparing expert and community practice
    Meeting Abstract

    Quill, T.; Hurvitz, S.; Miller, K. D.; O'Regan, R.; Traina, T. A.; Andrie, R.; Obholz, K. L.; Jahanzeb, M.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease
    Meeting Abstract

    Krop, I.; Masuda, N.; Kogawa, T.; Takahashi, S.; Yonemori, K.; Inoue, K.; Nakayama, T.; Yamamoto, Y.; Alvarez, R.; Toyama, T.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Genomic profiling of primary and metastatic breast cancer in men
    Meeting Abstract

    Drago, J. Z.; Serna-Tamayo, C.; Dos Anjos, C. H.; Brown, D. N.; Modi, S.; Jhaveri, K.; Solit, D. B.; Traina, T. A.; Chandarlapaty, S.; Reis-Filho, J. S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • PD-L1 expression in metaplastic breast carcinoma (MBC) using PD-L1 SP142 assay and concordance among PD-L1 immunohistochemical (IHC) assays
    Meeting Abstract

    Grabenstetter, A.; Jungbluth, A.; Frosina, D.; Hoda, R.; Weigelt, B.; Reis-Filho, J.; Zhang, H.; Traina, T.; Robson, M.; Brogi, E.; more...
    Laboratory Investigation (2020)

    Fulltext@MSK | Save
  • PD-L1 expression in tumor-infiltrating lymphocytes of invasive breast carcinoma
    Meeting Abstract

    Hoda, R.; Brogi, E.; Grabenstetter, A.; Patil, S.; Selenica, P.; Weigelt, B.; Reis-Filho, J.; Traina, T.; Robson, M.; Norton, L.; more...
    Laboratory Investigation (2020)

    Fulltext@MSK | Save
  • Multigene assays in early breast cancer: Insights from recent phase 3 studies
    Review

    Markopoulos, C.; Hyams, D. M.; Gomez, H. L.; Harries, M.; Nakamura, S.; Traina, T.; Katz, A.
    European Journal of Surgical Oncology (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of gemcitabine with trastuzumab and pertuzumab after prior pertuzumab-based therapy among patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A phase 2 clinical trial
    Journal Article

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Fornier, M. N.; Goldfarb, S.; Jhaveri, K.; more...
    JAMA Network Open (2019)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen receptor-positive (AR plus ) TNBC
    Meeting Abstract

    Traina, T. A.; Boyle, L. A.; Arumov, A.; Patil, S.; Edelweiss, M.; DeFusco, P. A.; Gorsky, M.; Lamparella, N. E.; Modi, S.; Sanford, R. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC)
    Meeting Abstract

    Sammons, S.; Tan, T. J. Y.; Traina, T. A.; Kim, S. B.; Im, Y. H.; Bachelder, C.; Marcom, P. K.; Dent, R. A.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC)
    Meeting Abstract

    Page, D. B.; Kim, I. K.; Chun, B.; Redmond, W. L.; Martel, M.; Mori, M.; Wadell, D.; Moxon, N.; Mellinger, S. L.; Urba, W. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save